MEF2D has been previously identified as a promoter of HCC advancement through cell cycle regulation, and this study enhances its significance in metabolic control, indicating it may function as a “master regulator” that integrates many oncogenic signals. This evidence concerns the gene MEF2D and hepatocellular carcinoma.